Skin and Soft Tissue Infections Market Size
The Global Skin and Soft Tissue Infections Market reached US$ 13357.02 million in 2025 and is expected to reach US$ 31045.5 million by 2035, growing at a CAGR of 8.8% during the forecast period 2026-2035.
Skin and Soft Tissue Infections (SSTI) are infections of the skin, muscles, and connective tissue such as ligaments and tendons. The most frequent cause of SSTIs is bacteria, which can enter the body through a variety of openings such as burns, tiny cuts, scrapes, and wounds from surgical sites.
Common simple SSTIs include cellulitis, erysipelas, impetigo, ecthyma, folliculitis, furuncles, carbuncles, abscesses, and trauma-related infections. Complicated infections include deep abscesses, decubitus ulcers, necrotizing fasciitis, Fournier gangrene, and infections from human or animal bites.
Skin and Soft Tissue Infections Market Key Takeaways
- Antibiotics remain central to treatment: The antibiotics segment holds a major market position because of its role in managing bacterial skin and soft tissue infections.
- Pharmaceutical innovation supports demand: The approval of Zevtera in April 2024 for specified bloodstream infections and ABSSSI demonstrates the relevance of expanded treatment applications in infectious disease care.
- Antimicrobial resistance is a commercial consideration: MRSA and VRE create treatment challenges that increase the importance of drug efficacy, therapeutic alternatives, and continued antimicrobial research.
- North America leads the regional landscape: Established healthcare infrastructure, pharmaceutical companies, and clinical treatment capabilities support the region's position.
- Asia-Pacific offers expansion potential: The source identifies Asia-Pacific as the fastest-growing region, making regional distribution, pharmaceutical access, and healthcare demand relevant to market participants.
- Distribution strategy matters: Hospital pharmacies and retail pharmacies serve different treatment and purchasing requirements, creating opportunities for suppliers to align product availability with clinical and consumer healthcare settings.
Skin and Soft Tissue Infections Market Scope
| Metric | Details |
Market Size (2025) | USD 13,357.02 Million |
Market Size (2035) | USD 31,045.50 Million |
CAGR (2026–2035) | 8.80% |
Historic Years | 2023–2024 |
Base Year | 2025 |
Forecast Period | 2026–2035 |
Market Revenue Unit | USD Million |
Segments Covered | Type, Drug Type, Route of Administration, Distribution Channel, and Region |
Leading Region | North America |
Fastest-Growing Region | Asia-Pacific |
For know more Insights - Download Sample
Skin and Soft Tissue Infections Market Dynamics: Drivers & Restraints
Rising product development and approvals
The rising developments and approvals of the drugs for the treatment of Skin and Soft Tissue Infections is expected to drive the market growth. With the development of new drugs there will be a wide range of products available for the individuals with the infections. This rises the demand for the new products for the treatment.
The rising product approvals with broad spectrum applications is expected to increase the demand for the drugs. For instance, in April 2024, the U.S. Food and Drug Administration approved Zevtera (ceftobiprole medocaril sodium for injection) for the treatment of adults with Staphylococcus aureus bloodstream infections (bacteremia) (SAB), including those with right-sided infective endocarditis, adults with acute bacterial skin and skin structure infections (ABSSSI).
Additionally, July 23, 2021, AbbVie received the U.S. Food and Drug Administration (FDA) approved DALVANCE (dalbavancin) for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in pediatric patients from birth. DALVANCE is the first single-dose option administered as a 30-minute intravenous (IV) infusion for the treatment of ABSSSI caused by designated susceptible Gram-positive bacteria in pediatric patients, including infections caused by methicillin-resistant Staphylococcus aureus (MRSA). Thus, the above factors could drive the market growth.
Resistance to the new strains of infectious bacteria
The emergence of antibiotic-resistant bacteria, such as vancomycin-resistant Enterococcus (VRE) and methicillin-resistant Staphylococcus aureus (MRSA), presents a major obstacle to the treatment of SSTIs. This reduces the effectiveness of conventional antibiotics, leading to extended therapy times, higher medical expenses, and worse patient outcomes.
Skin and Soft Tissue Infections Market Segment Analysis
The global Skin and Soft Tissue Infections market is segmented based on type, drug type, route of Administration, distribution channel and region.
Antibiotics segment is expected to dominate the market share
Antibiotics segment holds a major position in the market share. For bacterial SSTIs, antibiotics are currently the primary form of treatment. They function well against a variety of bacterial pathogens, including Streptococcus pyogenes and Staphylococcus aureus, that can lead to skin infections. Antibiotics specifically target bacterial infections, that are a common cause of SSTIs.
The large number of prescriptions for and treatments for bacterial infections has created an significant position for antibiotics.
The market position of antibiotics is further built by ongoing research and development activities in antibiotic therapy, which lead to the creation of novel formulations, combinations, and enhanced efficacy against antibiotic-resistant bacteria. Thus, the above factors are expected to drive the segment growth.
Skin and Soft Tissue Infections Market Geographical Share
North America is expected to hold a significant position in the skin and soft tissue infections market share
North America is holding a dominant position in the market share owing to the increasing incidence of several Skin and Soft Tissue Infections in the region. The presence of a large number of pharmaceutical companies in the region is also expected to be a factor in the growth of the region’s market.
The region has an advanced healthcare infrastructure with established hospitals and clinics. The hospitals and clinics have well-established diagnostic tools and the region also has well-established medical research and advancements in treatment options.
The increasing number of Skin and Soft Tissue Infections in the region increases demand for the new drugs that are developed in the region. For instance, according to the report by NIH in 2023, it is estimated that cellulitis is a very common skin infection that accounts for more than 14 million cases in the United States per year.
Additionally, according to the Agency for Healthcare Research and Quality, each year, more than 2.5 million people in the United States develop pressure ulcers. These skin lesions bring pain, associated risk for serious infection, and increased health care utilization. Pressure ulcers are associated with longer hospital stays and increased morbidity and mortality. Thus, the above factors are expected to hold the region in the dominant position.
Skin and Soft Tissue Infections Market Segmentation
By Type
- Infected Ulcers
- Wound Infections
- Abscesses
- Cellulitis
- Otitis Externa
- Others
By Drug Type
- Antibiotics
- Anti-fungal Agents
- Others
By Route of Administration
- Topical
- Oral
- Parenteral
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Others
By Region
- North America
- The U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe
- South America
- Brazil
- Argentina
- Rest of South America
- Asia-Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Middle East and Africa
Skin and Soft Tissue Infections Market Competitive Landscape
The major global players in the market include GSK Plc, Pfizer Inc., Merck KGaA, Wellona Pharma, GL Pharma, Basilea Pharmaceutica AG, Invision Medi Sciences Pvt. Ltd., Intelicure Lifesciences., Steris Healthcare Pvt Ltd and SNU Biocare among others.
Skin and Soft Tissue Infections Market Key Developments
September 2026: Globally, advanced antibiotic therapies are gaining attention for treating skin and soft tissue infections, including resistant bacterial infections and complicated cases.
September 2026: In North America, healthcare providers are emphasizing updated antibiotic treatment protocols, shorter treatment durations, antimicrobial stewardship, and targeted infection management.
August 2026: In Europe, research continued to focus on novel antibiotics, antimicrobial resistance, rapid diagnosis, and improved treatment strategies for complicated skin infections.
July 2026: Globally, MRSA-focused therapies and newer antibiotics such as dalbavancin, tedizolid, oritavancin, and delafloxacin remained important areas in resistant SSTI management.
June 2026: In Asia-Pacific, growing healthcare access and improved diagnostic capabilities are supporting the management of cellulitis, abscesses, diabetic foot infections, and other bacterial skin infections.
May 2026: Globally, research into topical nanoformulations, antimicrobial peptides, targeted drug delivery, and advanced wound-care solutions continued to support innovation in SSTI treatment.
April 2026: In North America and Europe, clinical management increasingly emphasized culture-guided antibiotic selection, infection severity assessment, and antimicrobial resistance monitoring.
March 2026: Globally, healthcare systems continued strengthening early diagnosis, infection prevention, antibiotic stewardship, and outpatient treatment pathways for skin and soft tissue infections.
Why Purchase the Report?
- To visualize the global skin and soft tissue infections market segmentation based on type, drug type, route of administration, distribution channel, and region as well as understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development.
- Excel data sheet with numerous data points of skin and soft tissue infections market-level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping available as Excel consisting of key products of all the major players.
The global skin and soft tissue infections market report would provide approximately 53 tables, 47 figures, and 176 pages.
Target Audience
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
